It was reported that a sodium–glucose cotransporter 2 (SGLT2) inhibitor, luseogliflozin, could attenuate vessel injuries and renal fibrosis through a VEGF-dependent pathway [34]. The gene discussed is VEGFA; the disease is renal fibrosis.